Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study.

Inoue K, Maeda N, Fujishima Y, Fukuda S, Nagao H, Yamaoka M, Hirata A, Nishizawa H, Funahashi T, Shimomura I.

Diabetol Metab Syndr. 2014 Sep 8;6(1):95. doi: 10.1186/1758-5996-6-95. eCollection 2014.

2.

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.

Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, Kozawa J, Yasuda T, Okita K, Imagawa A, Funahashi T, Shimomura I.

Cardiovasc Diabetol. 2012 Sep 14;11:107.

3.

Long-Term Effectiveness of Liraglutide in Association with Patients' Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study.

Berkovic MC, Bilic-Curcic I, Herman Mahecic D, Gradiser M, Grgurevic M, Bozek T.

Diabetes Ther. 2017 Dec;8(6):1297-1308. doi: 10.1007/s13300-017-0324-x. Epub 2017 Oct 26.

4.

Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes.

Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, Hiuge-Shimizu A, Okita K, Imagawa A, Funahashi T, Shimomura I.

Cardiovasc Diabetol. 2011 Dec 1;10:109. doi: 10.1186/1475-2840-10-109.

5.

Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting.

Kaur P, Mahendru S, Mithal A.

Indian J Endocrinol Metab. 2016 Sep-Oct;20(5):595-599.

6.

Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients.

Fadini GP, Simioni N, Frison V, Dal Pos M, Bettio M, Rocchini P, Avogaro A.

Acta Diabetol. 2013 Dec;50(6):943-9. doi: 10.1007/s00592-013-0489-3. Epub 2013 Jun 11.

PMID:
23754673
7.

Long-term effectiveness and safety of liraglutide in clinical practice.

Ponzani P.

Minerva Endocrinol. 2013 Mar;38(1):103-12.

PMID:
23435446
8.
9.

A higher body mass index attenuates the long-term HbA1c-lowering effects of liraglutide in type 2 diabetes patients treated using sulfonylurea-based therapy.

Yamamoto T, Fukui T, Higuchi A, Ohara M, Hayashi T, Hirano T.

Diabetol Int. 2016 Apr 13;7(4):425-431. doi: 10.1007/s13340-016-0269-8. eCollection 2016 Dec.

11.

Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.

Suzuki D, Toyoda M, Kimura M, Miyauchi M, Yamamoto N, Sato H, Tanaka E, Kuriyama Y, Miyatake H, Abe M, Umezono T, Fukagawa M.

Intern Med. 2013;52(10):1029-34. Epub 2013 May 15.

12.

A prospective study of concomitant GLP-1 analogue and insulin use in type 2 diabetes in clinical practice.

van Velsen EF, Lamers J, Blok V, van Leendert RJ, Kiewiet-Kemper RM.

Neth J Med. 2014 Dec;72(10):523-7.

13.

Is insulin the most effective injectable antihyperglycaemic therapy?

Buse JB, Peters A, Russell-Jones D, Furber S, Donsmark M, Han J, MacConell L, Maggs D, Diamant M.

Diabetes Obes Metab. 2015 Feb;17(2):145-51. doi: 10.1111/dom.12402. Epub 2014 Nov 9.

PMID:
25323312
14.

The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.

Lane W, Weinrib S, Rappaport J.

Diabetes Technol Ther. 2011 May;13(5):592-5. doi: 10.1089/dia.2010.0221. Epub 2011 Mar 15.

PMID:
21406014
15.

Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor.

de Luis DA, Diaz Soto G, Izaola O, Romero E.

J Diabetes Complications. 2015 May-Jun;29(4):595-8. doi: 10.1016/j.jdiacomp.2015.02.010. Epub 2015 Feb 25.

PMID:
25825013
16.
17.
18.

Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study.

Lapolla A, Berra C, Boemi M, Bossi AC, Candido R, Di Cianni G, Frontoni S, Genovese S, Ponzani P, Provenzano V, Russo GT, Sciangula L, Simioni N, Bette C, Nicolucci A; NN2211-4118 Study Group.

Adv Ther. 2018 Feb;35(2):243-253. doi: 10.1007/s12325-017-0652-2. Epub 2017 Dec 21.

19.

Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients.

Feng P, Yu DM, Chen LM, Chang BC, Ji QD, Li SY, Zhu M, Ding SH, Zhang BZ, Wang SL, Li HT, Lin JN, Wang MJ, Guo JC, Liu J, Liu ZD, Wu ST, Yang JH.

Acta Pharmacol Sin. 2015 Feb;36(2):200-8. doi: 10.1038/aps.2014.136. Epub 2015 Jan 26.

20.

An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes.

Gomez-Peralta F, Abreu C, Castro JC, Alcarria E, Cruz-Bravo M, Garcia-Llorente MJ, Albornos C, Moreno C, Cepeda M, Almodóvar F.

BMC Endocr Disord. 2015 Dec 4;15:78. doi: 10.1186/s12902-015-0074-6.

Supplemental Content

Support Center